{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:27:13Z","timestamp":1781220433101,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,30]]},"DOI":"10.1093\/infdis\/jix572","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T07:06:56Z","timestamp":1509952016000},"page":"597-607","source":"Crossref","is-referenced-by-count":68,"title":["Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial"],"prefix":"10.1093","volume":"217","author":[{"given":"Geert","family":"Leroux-Roels","sequence":"first","affiliation":[{"name":"Center for Vaccinology, Ghent University and University Hospital, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob P","family":"Cramer","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Mendelman","sequence":"additional","affiliation":[{"name":"Takeda Vaccines Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Clemens","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Aerssens","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Ghent University and University Hospital, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"De Coster","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Baehner","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"key":"key\n\t\t\t\t20180306104604_CIT0001","volume-title":"WHO estimates of the global burden of foodborne diseases","author":"Foodborne Disease Burden Epidemiology Reference Group 2007\u20132015"},{"key":"key\n\t\t\t\t20180306104604_CIT0002","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/JCM.01535-14","article-title":"Advances in laboratory methods for detection and typing of norovirus","volume":"53","author":"Vinj\u00e9","year":"2015","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180306104604_CIT0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1469-0691.2005.01299.x","article-title":"Risk groups for clinical complications of norovirus infections: an outbreak investigation","volume":"12","author":"Mattner","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306104604_CIT0004","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ajic.2012.08.002","article-title":"Clinical characteristics of norovirus-associated deaths: a systematic literature review","volume":"41","author":"Trivedi","year":"2013","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t20180306104604_CIT0005","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/119.6.668","article-title":"Winter vomiting disease","volume":"119","author":"Adler","year":"1969","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0006","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/1469-0691.12746","article-title":"Evolution of norovirus","volume":"20","author":"White","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306104604_CIT0007","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306104604_CIT0008","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0009","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1128\/JVI.02179-09","article-title":"Heterotypic humoral and cellular immune responses following Norwalk virus infection","volume":"84","author":"Lindesmith","year":"2010","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180306104604_CIT0010","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2012.03.050","article-title":"Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations","volume":"30","author":"Parra","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180306104604_CIT0011","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/657087","article-title":"Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues","volume":"202","author":"El-Kamary","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0012","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/infdis\/jiu337","article-title":"A novel intramuscular bivalent norovirus virus-like particle vaccine candidate\u2014reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults","volume":"210","author":"Treanor","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0013","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0014","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/656364","article-title":"Serological correlate of protection against norovirus-induced gastroenteritis","volume":"202","author":"Reeck","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306104604_CIT0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/CVI.00196-15","article-title":"Serological correlates of protection against a GII.4 norovirus","volume":"22","author":"Atmar","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20180306104604_CIT0016","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrmicro.2016.48","article-title":"Human norovirus transmission and evolution in a changing world","volume":"14","author":"de Graaf","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20180306104604_CIT0017","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20180306104604_CIT0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14712598.8.2.235","article-title":"Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients","volume":"8","author":"Beran","year":"2008","journal-title":"Expert Opin Biol Ther"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/217\/4\/597\/24263120\/jix572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T10:46:44Z","timestamp":1520333204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/217\/4\/597\/4623790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,13]]},"published-print":{"date-parts":[[2018,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix572","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,15]]},"published":{"date-parts":[[2017,11,13]]}}}